Volume 4 Supplement 2
Edited by Peter E Lipsky and Ravinder N Maini
Supported by an educational grant from Centocor, Inc.
Although functional outcome is frequently discussed and written about, it is often not clear what functional outcome is and how it can be measured. This paper introduces the concept of latent and observed meas...
With the introduction of new disease-modifying antirheumatic drugs (DMARDs) and other therapeutic agents, the management of rheumatoid arthritis (RA) has shifted toward earlier, more aggressive therapy. The ul...
Since the initial characterization of tumor necrosis factor alpha (TNFα), it has become clear that TNFα has diverse biologic activity. The realization that TNFα plays a role in rheumatoid arthritis (RA) has le...
Several agents show an effect on reducing radiographic progression in rheumatoid arthritis. It is tempting to retrospectively compare the effects of these agents on radiographic progression across clinical tri...
Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet bee...
Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine that has been implicated in a variety of rheumatic and inflammatory diseases. New understanding of the importance of TNF-α in the pathophysiology...
Early diagnosis of rheumatoid arthritis (RA) combined with early initiation of an appropriate treatment regimen is acknowledged as an important factor in improving clinical outcomes in patients with RA. Early ...
2022 Citation Impact
4.9 - 2-year Impact Factor
5.7 - 5-year Impact Factor
1.501 - SNIP (Source Normalized Impact per Paper)
1.592 - SJR (SCImago Journal Rank)
2022 Speed
7 days submission to first editorial decision for all manuscripts (Median)
149 days submission to accept (Median)
2022 Usage
3,146,404 downloads
17,226 Altmetric mentions